Phase III results of a single oral, 3-day oral, and 3-day iv/oral regimen of  casopitant, a novel neurikinin-1 (NK-1) receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)

Jørn Herrstedt, F. Roila, S. van Belle, R. R. Bandekar, J. Levin, S. M. Grunberg

Research output: Contribution to journalConference abstract in journalResearch

Original languageEnglish
JournalAnnals of Oncology. Supplement
Issue number8
Pages (from-to)viii 273
ISSN1572-610X
DOIs
Publication statusPublished - 2008
EventEuropean Society for Medical Oncology - Stockholm, Sweden
Duration: 12. Sep 200816. Sep 2008
Conference number: 33

Conference

ConferenceEuropean Society for Medical Oncology
Number33
CountrySweden
CityStockholm
Period12/09/200816/09/2008

Cite this

@article{658b58f0a02811dd9b31000ea68e967b,
title = "Phase III results of a single oral, 3-day oral, and 3-day iv/oral regimen of  casopitant, a novel neurikinin-1 (NK-1) receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)",
author = "J{\o}rn Herrstedt and F. Roila and {van Belle}, S. and Bandekar, {R. R.} and J. Levin and Grunberg, {S. M.}",
note = "Volumne: 19",
year = "2008",
doi = "10.1093/annonc/mdn524",
language = "English",
pages = "viii 273",
journal = "Annals of Oncology. Supplement",
issn = "1572-610X",
publisher = "Oxford University Press",
number = "8",

}

Phase III results of a single oral, 3-day oral, and 3-day iv/oral regimen of  casopitant, a novel neurikinin-1 (NK-1) receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC). / Herrstedt, Jørn; Roila, F.; van Belle, S.; Bandekar, R. R.; Levin, J.; Grunberg, S. M.

In: Annals of Oncology. Supplement, No. 8, 2008, p. viii 273.

Research output: Contribution to journalConference abstract in journalResearch

TY - ABST

T1 - Phase III results of a single oral, 3-day oral, and 3-day iv/oral regimen of  casopitant, a novel neurikinin-1 (NK-1) receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)

AU - Herrstedt, Jørn

AU - Roila, F.

AU - van Belle, S.

AU - Bandekar, R. R.

AU - Levin, J.

AU - Grunberg, S. M.

N1 - Volumne: 19

PY - 2008

Y1 - 2008

U2 - 10.1093/annonc/mdn524

DO - 10.1093/annonc/mdn524

M3 - Conference abstract in journal

SP - viii 273

JO - Annals of Oncology. Supplement

JF - Annals of Oncology. Supplement

SN - 1572-610X

IS - 8

ER -